| Zhe Zheng, | |
|
9001 Summa Ave, Baton Rouge, LA 70809-3726 | |
| (225) 761-5370 | |
| Not Available |
| Full Name | Zhe Zheng |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 31 Years |
| Location | 9001 Summa Ave, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083879175 | NPI | - | NPPES |
| 03434738 | Medicaid | MS | |
| 2368061 | Medicaid | LA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Medical Center - Baton Rouge | Baton rouge, LA | Hospital |
| Ochsner Clinic Foundation | New orleans, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ochsner Clinic Llc | 8224933619 | 2403 |
News Archive
Cancer cells have the ability to grow in an acidic tumor environment that is detrimental to other cells, including immune cells. In a Cancer Research cover article published this week, Moffitt Cancer Center reported that neutralizing the acidic tumor environment increases the efficacy of several immune-targeting cancer therapies.
A person playing a first-person shooter video game like Halo or Unreal Tournament must make decisions quickly. That fast-paced decision-making, it turns out, boosts the player's visual skills but comes at a cost, according to new research: reducing the person's ability to inhibit impulsive behavior.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Boston Scientific Corporation announces U.S. Food and Drug Administration approval and market launch of the Epic Vascular Self-Expanding Stent System.
According to a new study, high long-chain omega-3 polyunsaturated fatty acid content in blood may lower the risk of small brain infarcts and other brain abnormalities in the elderly.
› Verified 3 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
Cancer cells have the ability to grow in an acidic tumor environment that is detrimental to other cells, including immune cells. In a Cancer Research cover article published this week, Moffitt Cancer Center reported that neutralizing the acidic tumor environment increases the efficacy of several immune-targeting cancer therapies.
A person playing a first-person shooter video game like Halo or Unreal Tournament must make decisions quickly. That fast-paced decision-making, it turns out, boosts the player's visual skills but comes at a cost, according to new research: reducing the person's ability to inhibit impulsive behavior.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Boston Scientific Corporation announces U.S. Food and Drug Administration approval and market launch of the Epic Vascular Self-Expanding Stent System.
According to a new study, high long-chain omega-3 polyunsaturated fatty acid content in blood may lower the risk of small brain infarcts and other brain abnormalities in the elderly.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Zhe Zheng, 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-4000 | Zhe Zheng, 9001 Summa Ave, Baton Rouge, LA 70809-3726 Ph: (225) 761-5370 |
News Archive
Cancer cells have the ability to grow in an acidic tumor environment that is detrimental to other cells, including immune cells. In a Cancer Research cover article published this week, Moffitt Cancer Center reported that neutralizing the acidic tumor environment increases the efficacy of several immune-targeting cancer therapies.
A person playing a first-person shooter video game like Halo or Unreal Tournament must make decisions quickly. That fast-paced decision-making, it turns out, boosts the player's visual skills but comes at a cost, according to new research: reducing the person's ability to inhibit impulsive behavior.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Boston Scientific Corporation announces U.S. Food and Drug Administration approval and market launch of the Epic Vascular Self-Expanding Stent System.
According to a new study, high long-chain omega-3 polyunsaturated fatty acid content in blood may lower the risk of small brain infarcts and other brain abnormalities in the elderly.
› Verified 3 days ago
Dr. Jennifer L Rippon, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7777 Hennessy Blvd Ste 409, Baton Rouge, LA 70808 Phone: 225-765-5864 Fax: 225-765-2013 | |
Gregory Fusilier, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 9103 Jefferson Hwy, Baton Rouge, LA 70809 Phone: 225-927-1190 Fax: 225-927-0988 | |
Dr. Yolanda Maria O'rourke, Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 7968 Essen Park, Baton Rouge, LA 70809 Phone: 225-761-6700 Fax: 225-761-6760 | |
Patricia D. Whatley, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Attn: Dee / Administration, Baton Rouge, LA 70808 Phone: 225-769-4044 | |
Frederick Cerise, Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3810 W Lakeshore Dr, Baton Rouge, LA 70808 Phone: 225-578-8886 | |
Dr. Jon Richard Jackson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5000 Hennessy Blvd, Baton Rouge, LA 70808 Phone: 225-765-4050 Fax: 225-765-4046 | |
Richard Frank Burroughs, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Earl K. Long Hospital, Lsu Unit, 5825 Airline Highway, Baton Rouge, LA 70805 Phone: 225-358-3938 |